This preemptive strategy focuses on the risk that future iterations of AI could eventually be used to develop biological threats. By identifying and solving for these risks in advance, Red Queen Bio intends to mitigate the danger of man-made pathogens engineered by software.
Wednesday, October 21, 2026
Story
Red Queen Bio Designs Antibody Drugs for AI Generated Pathogens
Tech23 days ago
Potential pandemics caused by artificial intelligence are being targeted by the drug-design efforts of startup Red Queen Bio. The company utilizes artificial intelligence to engineer antibody treatments for novel pathogens in an attempt to ensure that medications exist before the diseases themselves are created.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.